{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:33Z","timestamp":1781308653740,"version":"3.54.1"},"reference-count":159,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Sickle cell disease comprises a group of prevalent inherited disorders defined by an underlying sickle cell allele that forms sickle hemoglobin. The incidence of this disease is rising, with more than 500,000 children born with it globally. The disease carries significant morbidity and mortality. Its only curative treatment was an allogeneic hematopoietic stem cell (HSC) transplant (HSCT) until late 2023, when two one-time gene therapies were approved for treating patients aged 12 years or older with severe sickle cell disease. This work aims to inform readers about these two gene therapies: one lentiviral-based and the other nonviral. The latter is based on the Nobel Prize-winning discovery of clustered, regularly interspaced, short, palindromic repeats (CRISPR)\/CRISPR-associated (Cas)9 proteins and single-guide RNA (sgRNA)-based genome editing. Both approved gene therapies require an autologous HSCT with ex vivo genetically edited autologous hematopoietic stem and progenitor cells. Therefore, access to these gene therapies is limited to specialized centers with expertise in HSCTs. This review is meant for students, researchers, and clinical practitioners. It explains the basis for both approved gene therapies, their mechanisms of action, differences, risks, and other lentiviral-based and CRISPR-Cas9-based ex vivo gene therapies for sickle cell disease in clinical development. Additionally, it discusses the current state of preclinical studies for in vivo HSC gene therapy for sickle cell disease, which utilize advanced genome editing technologies developed after CRISPR-Cas9-sgRNA-based genome editing. In vivo HSC gene therapy, after it is clinically developed, would eliminate the need for an HSCT in receiving gene therapy and vastly increase access for numerous patients worldwide, even in low-income countries with the most significant disease burden.<\/jats:p>","DOI":"10.3390\/genes16111367","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:56:27Z","timestamp":1762858587000},"page":"1367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Curing Sickle Cell Disease by Allogeneic Hematopoietic Stem Cell (HSC) Transplantation Toward In Vivo HSC Gene Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-3057","authenticated-orcid":false,"given":"Rina","family":"Kansal","sequence":"first","affiliation":[{"name":"Molecular Oncology and Genetics, Diagnostic Laboratories, Versiti Blood Center of Wisconsin, Milwaukee, WI 53233, USA"},{"name":"Department of Pathology and Anatomical Sciences, The University at Buffalo, Buffalo, NY 14260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Colombatti, R., Hegemann, I., Medici, M., and Birkeg\u00e5rd, C. (2023). Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175538"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ejh.13512","article-title":"Changing patterns in the epidemiology of \u03b2-thalassemia","volume":"105","author":"Kattamis","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.hoc.2022.11.001","article-title":"Introduction to the Thalassemia Syndromes: Molecular Medicine\u2019s Index Case","volume":"37","author":"Benz","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.hoc.2022.12.001","article-title":"Molecular Basis and Genetic Modifiers of Thalassemia","volume":"37","author":"Tesio","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"beta-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0140-6736(22)00536-0","article-title":"Thalassaemia","volume":"399","author":"Kattamis","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2018-06-848705","article-title":"The current state of sickle cell trait: Implications for reproductive and genetic counseling","volume":"132","author":"Pecker","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref_12","unstructured":"GBD 2021 Sickle Cell Disease Collaborators (2023). Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: A systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol., 10, e585\u2013e599."},{"key":"ref_13","unstructured":"United States Centers for Disease Control and Prevention Data and Statistics on Sickle Cell Disease, Available online: https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html."},{"key":"ref_14","unstructured":"Sickle Cell Disease Association of America, Inc Sickle Cell Disease FAQs, Available online: https:\/\/www.sicklecelldisease.org\/sickle-cell-health-and-disease\/faqs\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: A neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am. J. Prev. Med."},{"key":"ref_16","first-page":"546","article-title":"Infections in sickle cell disease","volume":"110","author":"Scourfield","year":"2025","journal-title":"Haematologica"},{"key":"ref_17","first-page":"289","article-title":"Pneumococcal sepsis in children with sickle cell disease","volume":"76","year":"1984","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pbc.22461","article-title":"Susceptibility to invasive bacterial infections in children with sickle cell disease","volume":"55","author":"Battersby","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3324\/haematol.2014.120030","article-title":"Environmental determinants of severity in sickle cell disease","volume":"100","author":"Tewari","year":"2015","journal-title":"Haematologica"},{"key":"ref_20","first-page":"230","article-title":"New ASH initiatives to improve patient care in the long-overlooked sickle cell disease","volume":"142","author":"Tubman","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/bloodadvances.2022009202","article-title":"Long-term survival with sickle cell disease: A nationwide cohort study of Medicare and Medicaid beneficiaries","volume":"7","author":"Jiao","year":"2023","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: A pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2440599","DOI":"10.1001\/jamanetworkopen.2024.40599","article-title":"Social Vulnerability and Sickle Cell Disease Mortality in the US","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","article-title":"Defining global strategies to improve outcomes in sickle cell disease: A Lancet Haematology Commission","volume":"10","author":"Piel","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_26","unstructured":"The World Health Organization Sickle Cell Disease, Available online: https:\/\/www.afro.who.int\/health-topics\/sickle-cell-disease."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e250064","DOI":"10.1001\/jamahealthforum.2025.0064","article-title":"Newborn Screening for Sickle Cell Disease and Thalassemia","volume":"6","author":"Quarmyne","year":"2025","journal-title":"JAMA Health Forum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bjh.15600","article-title":"with the endorsement of EuroBloodNet, the European Reference Network in Rare Haematological Diseases. Newborn screening for sickle cell disease in Europe: Recommendations from a Pan-European Consensus Conference","volume":"183","author":"Lobitz","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/hematology.2024000548","article-title":"Newborn screening initiatives for sickle cell disease in Africa","volume":"2024","author":"Nnodu","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Okeke, C.O., Okeke, C., Asala, S., Ofakunrin, A.O.D., Ufelle, S., and Nnodu, O.E. (2024). Sustainability of newborn screening for sickle cell disease in resource-poor countries: A systematic review. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0305110"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S4026","DOI":"10.4103\/jpbs.jpbs_1397_24","article-title":"The Neonatal Screening for Sickle Cell Disease, Thalassemia, and G6PD Deficiency in Central India","volume":"16","author":"Jha","year":"2024","journal-title":"J. Pharm. Bioallied Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Surve, S., Thakor, M., Madkaikar, M., Kaur, H., Desai, S., Shanmugam, R., Mohanty, S.S., Pandey, A., Salomi Kerketta, A., and Dave, K. (2025). Protocol for a Multicentric Cohort Study on Neonatal Screening and Early Interventions for Sickle Cell Disease Among High-Prevalence States of India. Diagnostics, 15.","DOI":"10.3390\/diagnostics15060730"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"El-Haj, N., and Hoppe, C.C. (2018). Newborn Screening for SCD in the USA and Canada. Int. J. Neonatal Screen., 4.","DOI":"10.3390\/ijns4040036"},{"key":"ref_34","unstructured":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action, and Martinez, R.M. (2020). Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action, National Academies Press (US)."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Galadanci, N., Phillips, S., Schlenz, A., Ivankova, N., and Kanter, J. (2024). Current Methods of Newborn Screening Follow-Up for Sickle Cell Disease Are Highly Variable and without Quality Assurance: Results from the ENHANCE Study. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10010022"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez de Aledo-Castillo, J.M., Argudo-Ram\u00edrez, A., Beneitez-Pastor, D., Collado-Gimbert, A., Almaz\u00e1n Castro, F., Roig-Bosch, S., Andr\u00e9s-Mas\u00f3, A., Ruiz-Llobet, A., Pedrals-Portabella, G., and Medina-Santamaria, D. (2024). Newborn Screening for Sickle Cell Disease in Catalonia between 2015-Epidemiology and Impact on Clinical Events. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10040069"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Petigas, L., Seck, N., Doupa, D., Diagne, I., and Roth-Kleiner, M. (2025). Findings supporting neonatal screening for sickle cell disease: An observational study in Senegal. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1578570"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/jha2.926","article-title":"Positive impacts of universal newborn screening on the outcome of children with sickle cell disease in the province of Quebec: A retrospective cohort study","volume":"5","author":"Kazadi","year":"2024","journal-title":"EJHaem"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle Cell Disease: A Review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41397-018-0045-1","article-title":"Hydroxyurea in the management of sickle cell disease: Pharmacogenomics and enzymatic metabolism","volume":"18","author":"Adorno","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17512433.2024.2390915","article-title":"Hydroxyurea in the sickle cell disease modern era","volume":"17","author":"Riley","year":"2024","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"HOPE Trial Investigators. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","unstructured":"Sickle Cell Disease Association of America, Inc. (SCDAA) (2024). Medical and Research Advisory Committee (MARAC) Statement: Pfizer\u2019s Voxelotor (Oxbryta\u00ae) Withdrawal, Available online: https:\/\/www.sicklecelldisease.org\/2024\/09\/28\/marac-statement-oxbryta\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2024000678","article-title":"Sickle cell disease in India: The journey and hope for the future","volume":"2024","author":"Gupta","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/phar.2792","article-title":"Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges","volume":"43","author":"Dexter","year":"2023","journal-title":"Pharmacotherapy"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Keza, G.K., Diallo, D.A., Diagne, I., de Montalembert, M., Corbasson, A., Bernaudin, F., Ranque, B., Coulibaly, B., Frederic, G., and Diop, S. (2023). Availability and Cost of Basic Drugs for Sickle Cell Disease in 13 African Countries. Blood, 142.","DOI":"10.1182\/blood-2023-188652"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_51","unstructured":"American Society of Gene Plus Cell Therapy Patient Education Gene Therapy Approaches, Available online: https:\/\/patienteducation.asgct.org\/gene-therapy-101\/gene-therapy-approaches."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.copbio.2018.11.016","article-title":"Gene therapy for blood diseases","volume":"60","author":"Kohn","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"(2011). Move over ZFNs. Nat. Biotechnol., 29, 681\u2013684.","DOI":"10.1038\/nbt.1935"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41573-020-00096-y","article-title":"Gene-editing pipeline takes off","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kansal, R. (2024). The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies. Genes, 15.","DOI":"10.20944\/preprints202406.0537.v1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-1-0716-2301-5_2","article-title":"Tools for Efficient Genome Editing; ZFN, TALEN, and CRISPR","volume":"2495","author":"Shamshirgaran","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: A decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/d41573-022-00124-z","article-title":"Base editors hit the clinic","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/d41573-022-00176-1","article-title":"Lentiviral vector gene therapies come of age with two FDA approvals","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene Autotemcel Gene Therapy for Non-\u03b20\/\u03b20 Genotype \u03b2-Thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_65","unstructured":"(2023). MHRA Authorises World-First Gene Therapy that Aims to Cure Sickle-Cell Disease and Transfusion-Dependent \u03b2-Thalassemia. The UK Medicines and Healthcare Products Regulatory Agency Press Release, Available online: https:\/\/www.gov.uk\/government\/news\/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia."},{"key":"ref_66","unstructured":"(2023). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. US Food and Drug Administration News Release, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.12968\/hmed.2019.80.1.33","article-title":"Haematopoietic stem cell transplants: Principles and indications","volume":"80","author":"Balassa","year":"2019","journal-title":"Br. J. Hosp. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Eurocord, the Pediatric Working Party of the European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research. Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbmt.2015.08.036","article-title":"Nonmyeloablative Stem Cell Transplantation with Alemtuzumab\/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease","volume":"22","author":"Saraf","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","article-title":"Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease","volume":"55","author":"Guilcher","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2025.02.021","article-title":"Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease","volume":"31","author":"Inam","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: A retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_78","first-page":"27","article-title":"Availability of related donors for bone marrow transplantation in sickle cell anemia","volume":"16","author":"Mentzer","year":"1994","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"ref_79","unstructured":"New York State Department of Health The Need for Blood Stem Cell Donors, Available online: https:\/\/www.health.ny.gov\/professionals\/patients\/donation\/bone_marrow\/."},{"key":"ref_80","unstructured":"National Marrow Donor Program. Available online: https:\/\/bethematch.org\/transplant-basics\/how-blood-stem-cell-transplants-work\/how-does-a-patients-ethnic-background-affect-matching\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbmt.2015.10.017","article-title":"Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"22","author":"Walters","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/asheducation-2013.1.370","article-title":"Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease","volume":"2013","author":"Gluckman","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical Bone Marrow Transplantation for Sickle Cell Disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: Working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Payen","year":"2010","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J. R. Soc. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e156060","DOI":"10.1172\/JCI156060","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"132","author":"Liggett","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"138","author":"Pincez","year":"2021","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2163357","DOI":"10.1080\/16078454.2022.2163357","article-title":"A systematic review comparing allogeneic hematopoietic stem cell transplant to gene therapy in sickle cell disease","volume":"28","author":"Rotin","year":"2023","journal-title":"Hematology"},{"key":"ref_98","unstructured":"United States Food and Drug Administration (2020). Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_100","unstructured":"Stein, R. Sickle Cell Patient\u2019s Success with Gene Editing Raises Hopes and Questions. Available online: https:\/\/www.npr.org\/sections\/health-shots\/2023\/03\/16\/1163104822\/crispr-gene-editing-sickle-cell-success-cost-ethics."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng2108","article-title":"A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15","volume":"39","author":"Menzel","year":"2007","journal-title":"Nat Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ni925","article-title":"Bcl11a is essential for normal lymphoid development","volume":"4","author":"Liu","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Shen, Y., Li, R., Teichert, K., Montbleau, K.E., Verboon, J.M., Voit, R.A., and Sankaran, V.G. (2021). Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing. PLoS Genet., 17.","DOI":"10.1371\/journal.pgen.1009835"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1126\/science.1211053","article-title":"Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing","volume":"334","author":"Xu","year":"2011","journal-title":"Science"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2016-08-736249","article-title":"Strict in vivo specificity of the Bcl11a erythroid enhancer","volume":"128","author":"Smith","year":"2016","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","article-title":"Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells","volume":"4","author":"Chang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2013-11-539981","article-title":"\u201cPackaging\u201d of fetal hemoglobin in sickle cell anemia","volume":"123","author":"Buchanan","year":"2014","journal-title":"Blood"},{"key":"ref_113","unstructured":"Biopharma Dive Pricey New Gene Therapies for Sickle Cell Pose Access Test. 2023. Available online: https:\/\/www.biopharmadive.com\/news\/crispr-sickle-cell-price-millions-gene-therapy-vertex-bluebird\/702066\/."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.370.6514.271","article-title":"A cut above: Pair that developed CRISPR earns historic award","volume":"370","author":"Cohen","year":"2020","journal-title":"Science"},{"key":"ref_115","unstructured":"United States Food and Drug Administration (2024). Summary Basis for Regulatory Action, Available online: https:\/\/www.fda.gov\/media\/175842\/download?attachment."},{"key":"ref_116","unstructured":"The National Human Genome Research Institute Sickle Cell Disease Gene Therapy FAQ, Available online: https:\/\/www.genome.gov\/sites\/default\/files\/media\/files\/2022-09\/Sickle_cell_disease_gene_therapy_FAQ_0.pdf."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1182\/bloodadvances.2023009680","article-title":"Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease","volume":"7","author":"Yang","year":"2023","journal-title":"Blood Adv."},{"key":"ref_118","unstructured":"Individuals with Severe Sickle Cell Disease Express High Risk Tolerance for Gene Therapies. American Society of Hematology Press Release. Available online: https:\/\/www.hematology.org\/newsroom\/press-releases\/2023\/individuals-with-severe-sickle-cell-disease-express-high-risk-tolerance-for-gene-therapies."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1182\/bloodadvances.2024012963","article-title":"Listening to patients and parents with sickle cell disease: The totality of gene therapy risks may outweigh the perceived benefits","volume":"8","author":"Johnson","year":"2024","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMc2313119","article-title":"Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel","volume":"390","author":"Yen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40273-024-01385-9","article-title":"Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States","volume":"42","author":"Herring","year":"2024","journal-title":"Pharmacoeconomics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M23-1520","article-title":"Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis","volume":"177","author":"Basu","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtm.2018.08.003","article-title":"Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with \u03b2-Thalassemia Major","volume":"10","author":"Psatha","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Lessard, S., Rimmel\u00e9, P., Ling, H., Moran, K., Vieira, B., Lin, Y.D., Rajani, G.M., Hong, V., Reik, A., and Boismenu, R. (2024). Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-74716-7"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: A phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.1998.tb10460.x","article-title":"Molecular basis of hereditary persistence of fetal hemoglobin","volume":"850","author":"Forget","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Steinberg, M.H. (2020). Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113782"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e65421","DOI":"10.7554\/eLife.65421","article-title":"Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin","volume":"11","author":"Ravi","year":"2022","journal-title":"Elife"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_136","unstructured":"Krigel, M. Novel Gene Therapy Trial for Sickle Cell Disease Launches. Available online: https:\/\/www.ucsf.edu\/news\/2024\/11\/428941\/novel-gene-therapy-trial-sickle-cell-disease-launches."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"104374","DOI":"10.1016\/j.isci.2022.104374","article-title":"High-level correction of the sickle mutation is amplified in vivo during erythroid differentiation","volume":"25","author":"Magis","year":"2022","journal-title":"iScience"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ymthe.2019.05.014","article-title":"Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates","volume":"27","author":"Romero","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"eabf2444","DOI":"10.1126\/scitranslmed.abf2444","article-title":"Development of \u03b2-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease","volume":"13","author":"Lattanzi","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice","volume":"7","author":"Everette","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_143","first-page":"572","article-title":"Studies of Exagamglogene Autotemcel\u2014Age and Place","volume":"391","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Rulu, P., and Tabassum, H. (2025). A Delphi study to identify and prioritize research areas in sickle cell disease in India. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-01338-y"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2018.02.004","article-title":"Integrating HDAd5\/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies","volume":"9","author":"Li","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_146","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.ymthe.2019.08.006","article-title":"Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In Vivo HSC Transduction with HDAd5\/35++ Vectors","volume":"27","author":"Li","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omtm.2021.12.003","article-title":"Safe and efficient in vivo hematopoietic stem cell transduction in nonhuman primates using HDAd5\/35++ vectors","volume":"24","author":"Li","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2024012757","article-title":"A simplified G-CSF-free procedure allows for in vivo HSC gene therapy of sickle cell disease in a mouse model","volume":"8","author":"Li","year":"2024","journal-title":"Blood Adv."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.ymthe.2024.10.018","article-title":"Introducing a hemoglobin G-Makassar variant in HSCs by in vivo base editing treats sickle cell disease in mice","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"Flomenberg","year":"2005","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2006-11-053710","article-title":"Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression","volume":"110","author":"Ball","year":"2007","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e2002022","DOI":"10.1002\/adhm.202002022","article-title":"Therapeutic RNA Delivery for COVID and Other Diseases","volume":"10","author":"Dobrowolski","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.omtn.2025.102622","article-title":"In vivo precision base editing to rescue mouse models of disease","volume":"36","author":"Schindeler","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Tozzi, L., Schiroli, G., Heshmati, Y., Cao, Y., Monte, M.T., Wangweerawong, A., Rottman, J.B., Palchaudhuri, R., Ribeil, J.-A., and Manis, J. (2024). In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers. Blood, 144.","DOI":"10.1182\/blood-2024-208626"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/11\/1367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T11:08:54Z","timestamp":1762859334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/11\/1367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":159,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["genes16111367"],"URL":"https:\/\/doi.org\/10.3390\/genes16111367","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}